In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Market Intelligence Research & Development Regenerative Medicine

Snapshot: February Highlights

  • News

Executive Summary

A selection of articles you might have missed from February 2022, including exclusive interviews and a look at the gene editing pipeline.

You may also be interested in...



Snapshot: April Highlights

A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series. 

Transforming Patient Engagement At Novartis

Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action. 

In Vivo's 2022 Rising Leaders At A Glance

Top 30 Leaders: see the list of entrepreneurs and innovators highlighted in the third edition of In Vivo's Rising Leaders series. 

Table

View full table

Topics

Tags:
Market Intelligence Research & Development Regenerative Medicine
Latest News

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Funding The Future: Accelerating The Long Walk To Innovation

Micro-Dosing Gene Therapy: A Recipe For Success?

Snapshot: June Highlights

UsernamePublicRestriction

Register

IV125034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By